CVD: Covance Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 1, 7:36 PM More on Covance (CVD): Q1 beats on all counts as total sales rose 9.3% Y/Y. Net profit jumped 35% on solid sales growth in its late-stage development business - which saw revenue grow by 17% - led by strength in its central laboratories and clinical development units. For the year, the company ups its EPS forecast to between $3 to $3.20 on revenue growth in the high-single digits. It previously had estimated earnings of around $2.85 to $3.15 and revenue growth in the mid-to-high single digits. Comment! [Earnings, Healthcare]
Wednesday, May 1, 4:53 PM Covance (CVD): Q1 EPS of $0.75 beats by $0.03. Net Revenue of $580.2M beats by $11.19M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 1, 12:10 AM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP Comment! [Earnings]
Tuesday, April 30, 5:35 PM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP 2 Comments [Earnings]
Thursday, January 24, 4:44 PM More on Covance (CVD): Q4 beats across the board. Net proftit rose 5.6% Y/Y, led by 22% growth in clinical development and 16% growth in its central laboratories business, which more than offset a decline in market access services. Late-Stage Development operating margins increased 130 basis points both year-on-year and sequentially to 21.3%. In Early Development, pro forma revenue of $216M and pro forma operating margin of 12.0% declined modestly from the previous quarter on lower demand for discovery support services. Comment! [Healthcare, Earnings]
Thursday, January 24, 4:41 PM Covance (CVD): Q4 EPS of $0.73 beats by $0.02. Net Revenue of $562M beats by $12.16M. (PR) Comment! [Earnings, Healthcare, Breaking News]
Tuesday, December 4, 2012, 2:53 PM Covance (CVD -0.2%) says its early development facility located in Shanghai, China, has received a Good Laboratory Practice Certificate from the Chinese State Food and Drug Administration. The facility provides nonclinical safety assessment, bioanalytical, in vivo pharmacology, and DMPK services. 1 Comment [Healthcare, Global & FX]
Monday, November 5, 2012, 5:41 PM More on Covance (CVD): Q3 came in mixed, beating on a per share basis but missing on top-line revenue estimates. Net profit fell 7.1% Y/Y as the drug-research outsourcing firm was negatively impacted by restructuring costs and other charges, which offset revenue growth in its late-stage development business. For the year, the company narrowed its EPS estimate to between $2.65 to $2.70, down from prior estimates of $2.50 to $2.70. Shares -0.2% AH. Comment! [Healthcare, Earnings]
Monday, November 5, 2012, 5:14 PM Covance (CVD): Q3 EPS of $0.72 beats by $0.05. Proforma Revenue of $542M (+3.2% Y/Y) misses by $5M. (PR) Comment! [Earnings, Healthcare]
Wednesday, July 25, 2012, 5:06 PM Covance (CVD): Q2 EPS of $0.65 beats by $0.01. Revenue of $543M (+6.8% Y/Y) beats by $0.29M. (PR) Comment! [Earnings, Healthcare]
Wednesday, May 2, 2012, 5:17 PM Covance (CVD): Q1 EPS of $0.06 in-line. Revenue of $530M (+5.7% Y/Y) misses by $1M. (PR) Comment! [Earnings]
Wednesday, January 25, 2012, 4:31 PM Covance (CVD) Q4 EPS of $0.73 in-line. Revenue of $582.4M (+8.3% Y/Y) beats by $38M. Shares -4.5% AH. (PR) Comment! [Earnings, Healthcare]
Thursday, November 3, 2011, 3:26 PM Drug research firm Covance (CVD -2.4%) trades lower, erasing an early 4% gain on solid Q3 results as revenue grew in both segments. Operating margin swung to 9.4% from negative 16.1%. The company also narrows its full-year earnings estimate from between $2.60 - $2.80 to $2.70. Comment! [Healthcare, On the Move]
Tuesday, September 28, 2010, 4:28 PM Drug developer Covance (CVD) authorizes a $250M share buyback, about 10% of common shares. CVD +1.1% AH. (PR) Comment!
Wednesday, April 29, 2009, 4:39 PM Covance (CVD): Q1 EPS of $0.63 beats by $0.02. Revenue of $441M vs. $429M. Sees full-year EPS of $2.50-2.70 vs. consensus of $2.88. Shares -8.2% AH. (PR) Comment!
Wednesday, April 29, 2009, 3:10 PM Notable earnings after Wednesday's close: AEM, AFL, AIZ, AKAM, AMKR, ANH, ARRS, AVB, BDN, BMR, BXP, CBG, CBL, CCI, CDNS, CLF, CNQR, CTXS, CVD, DRC, DRE, DTE, EQR, ERJ, ESRX, ESS, FLEX, FLS, FSLR, GERN, GNK, HAR, HGSI, HIW, ICO, JDSU, LSI, O, OI, OII, OKE, ORLY, OSIP, PLD, STR, RYL, SBUX, STM, TCO, TER, TRN, UNM, URI, V, VAR, WLL, WLT, WSH Comment!

CVD Covance Inc.

CVD

Covance Inc.